The state of PrEP accessibility

Check out my latest story for Healthline: Dr. Hyman Scott, MPH, the clinical research medical director at Bridge HIV and an assistant clinical professor of medicine at UCSF, and Dr. Kristin Englund, an infectious disease expert at Cleveland Clinic, contextualized the recent news that Gilead Sciences is donating enough HIV prevention drug Truvada to the CDC to benefit 200,000 people at risk for HIV.

Both stress that these efforts are laudable but much more needs to be done to make pre-exposure prophylaxis (PrEP)  treatment accessible, especially to those people at-risk for HIV who face socioeconomic, systemic barriers to accessing the care they need. More at the link here.

Screen Shot 2019-05-21 at 5.52.09 PM.png